Related Experiment Video
Updated: Aug 14, 2026
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane
Evanthia Bernitsas1, Wei Wei, Daniel D Mikol
1Department of Neurology, University of Michigan, 1500 E. Medical Center Drive, Ann Arbor, MI 48109-0322, USA.
Objective:
To explore the potential of dexrazoxane to suppress subclinical cardiotoxicity in MS patients receiving mitoxantrone.
Methods:
An open-label study was performed to evaluate possible subclinical cardiotoxicity in multiple sclerosis patients treated quarterly with mitoxantrone (48 mg/m(2) cumulative), with and without concomitant dexrazoxane, using blinded serial radionucleide ventriculography.
Results:
No patient experienced symptoms of heart failure. Patients receiving dexrazoxane, which is cardioprotective for anthracyclines, exhibited a significantly lesser decline in left ventricular ejection fraction (mean change, -3.80% vs -8.55%, p < 0.001).
Interpretation:
These results support a cardioprotective effect of dexrazoxane in mitoxantrone treated multiple sclerosis patients.
